Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026)

Ovid Therapeutics has reported Return on Capital Employed for 10 years, with the latest figure at 27.67% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 4580.0% year-over-year to 27.67%; the trailing twelve-month figure through Mar 2026 stood at 27.67% (up 4580.0% YoY), and the FY2025 full-year result was 37.47%, up 2006.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 27.67%, up from 42.82% in the prior quarter.
• The five-year high for Return on Capital Employed was 27.67% in Q1 2026, with the low at 73.47% in Q1 2025.
• Historically, Return on Capital Employed has averaged 51.83% across 5 years, with a median of 48.06% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 10304 bps — and 2026, when it jumped 4580 bps.
• Ovid Therapeutics' Return on Capital Employed stood at 36.27% in 2022, then slumped by 33 bps to 48.17% in 2023, then sank by 48 bps to 71.22% in 2024, then surged by 40 bps to 42.82% in 2025, then surged by 35 bps to 27.67% in 2026.
• The last three Return on Capital Employed figures came in at 27.67% (Q1 2026), 42.82% (Q4 2025), and 64.01% (Q3 2025), per Business Quant data.